Matthew Campbell, Associate Professor of Medicine at UT MD Anderson Cancer Center, shared a post on LinkedIn:
“Excited to share our publication in JCO Precision Oncology, highlighting the activity of single-agent PD-1 or PDL-1 immune checkpoint therapy in patients with mismatch repair deficiency or microsatellite instability upper tract urothelial cancer. Proud of Dr Mohammad Jad ‘MJ’ Moussa, Dr Alexander Andreev-Drakhlin, Dr Omar Alhalabi and entire team. Appreciate partnership with Dr Surena Matin.
Highlights n= 24 pts median FU 57 months
ORR 83%, complete responses in 16 pts
PFS rate at 12 month 95% and 24 month 78%
Durable remissions were seen with patients experiencing treatment free survival .”
Title: Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability
Authors: Mohammad Jad Moussa, Alexander Andreev-Drakhlin, Aradhana Venkatesan, Surena Matin, Lianchun Xiao, Rebecca Tidwell, Amishi Shah, Ana Adriazola, Leah Shaw, Jianjun Gao, John Lin, Sangeeta Goswami, Pavlos Msaouel, Charles Guo, Nizar Tannir, Arlene Siefker-Radtke, Omar Alhalabi, Matthew Campbell
Other articles about UTUC on OncoDaily.